These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 6591221)

  • 1. Haloperidol concentrations elevated in Chinese patients.
    Potkin SG; Shen Y; Pardes H; Phelps BH; Zhou D; Shu L; Korpi E; Wyatt RJ
    Psychiatry Res; 1984 Jun; 12(2):167-72. PubMed ID: 6591221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients.
    Lin KM; Poland RE; Nuccio I; Matsuda K; Hathuc N; Su TP; Fu P
    Am J Psychiatry; 1989 Oct; 146(10):1307-11. PubMed ID: 2782476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethnic comparison of haloperidol and reduced haloperidol plasma levels: Taiwan Chinese versus American non-Chinese.
    Chang WH; Jann MW; Hwu HG; Chen TY; Lin SK; Wang JM; Ereshefsky L; Saklad SR; Richards AL; Lam YW
    J Formos Med Assoc; 1991 Jun; 90(6):572-8. PubMed ID: 1681004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients.
    Jann MW; Chang WH; Davis CM; Chen TY; Deng HC; Lung FW; Ereshefsky L; Saklad SR; Richards AL
    Psychiatry Res; 1989 Oct; 30(1):45-52. PubMed ID: 2594870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of dopamine receptor blocking assay with plasma drug levels of haloperidol in schizophrenic patients.
    Kurland AA; Nagaraju A; Hanlon TE; Wilkinson EH; Ng KT
    J Clin Pharmacol; 1981 Jan; 21(1):42-7. PubMed ID: 7217342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol.
    Zhang-Wong J; Beiser M; Zipursky RB; Bean G
    Psychiatry Res; 1998 Dec; 81(3):333-9. PubMed ID: 9925184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients.
    Newton JE; Cannon DJ; Couch L; Fody EP; McMillan DE; Metzer WS; Paige SR; Reid GM; Summers BN
    J Clin Psychiatry; 1989 Apr; 50(4):132-5. PubMed ID: 2925601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol.
    Chang WH; Shieh YS; Liu HC; Jann MW; Chien CP
    Eur Neuropsychopharmacol; 1994 Jun; 4(2):119-26. PubMed ID: 7919941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroleptic radioreceptor activity and clinical outcome in schizophrenia.
    Contreras S; Alexander H; Faber R; Bowden C
    J Clin Psychopharmacol; 1987 Apr; 7(2):95-8. PubMed ID: 3584527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of haloperidol plasma concentrations between twice-a-day and once-a-day dosing in Chinese schizophrenic patients.
    Lin SK; Chen CH; Chang WH
    J Formos Med Assoc; 1993 Sep; 92(9):832-4. PubMed ID: 7904867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RBC and plasma levels of haloperidol and clinical response in schizophrenia.
    Smith RC; Vroulis G; Shvartsburd A; Allen R; Lewis N; Schoolar JC; Chojnacki M; Johnson R
    Am J Psychiatry; 1982 Aug; 139(8):1054-6. PubMed ID: 7091432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
    Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
    J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients.
    Lane HY; Hu OY; Jann MW; Deng HC; Lin HN; Chang WH
    Psychiatry Res; 1997 Mar; 69(2-3):105-11. PubMed ID: 9109178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study.
    McEvoy JP; Stiller RL; Farr R
    J Clin Psychopharmacol; 1986 Jun; 6(3):133-8. PubMed ID: 3711363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent reduced haloperidol/haloperidol ratios in schizophrenic patients.
    Chang WH; Hwu HG; Lane HY; Lin SK; Chen TY; Chen H; Wei HL; Lin WL; Lin HN
    Psychiatry Res; 1991 Sep; 38(3):215-25. PubMed ID: 1754634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haloperidol and prolactin concentrations in Asians and Caucasians.
    Lin KM; Poland RE; Lau JK; Rubin RT
    J Clin Psychopharmacol; 1988 Jun; 8(3):195-201. PubMed ID: 3379143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability of serum neuroleptic and prolactin concentrations during short- and long-term treatment of schizophrenic patients.
    Rao ML; Brown WA
    Psychopharmacology (Berl); 1987; 93(2):237-42. PubMed ID: 2892222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of haloperidol and reduced haloperidol in the plasma and blood of patients on depot haloperidol.
    Eyles DW; Whiteford HA; Stedman TJ; Pond SM
    Psychopharmacology (Berl); 1992; 106(2):268-74. PubMed ID: 1549652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between plasma haloperidol concentrations and clinical results.
    Palao DJ; Araúxo A; Haro JM; Brunet M; Bernardo M
    Arch Gen Psychiatry; 1996 Dec; 53(12):1167-9. PubMed ID: 8956684
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia.
    Santos JL; Cabranes JA; Vazquez C; Fuentenebro F; Almoguera I; Ramos JA
    Biol Psychiatry; 1989 Aug; 26(4):381-8. PubMed ID: 2669981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.